Prime Therapeutics' studies find cholesterollowering statins are underused
ST. PAUL Minn. Oct. 26 2015 PRNewswire &160;Nationally approximately half of patients prescribed statins as a cholesterol lowering therapy discontinue use within the first year and adherence...
View ArticleNew study Prime Therapeutics' Medication Therapy Management program increases...
ST. PAUL Minn. Oct. 26 2015 PRNewswire &160;Prime Therapeutics' LLC Prime researchers found up to a 40 percent higher proportion of adherent Medicare members among those participating in a...
View ArticleICER panel PCSK9s' value low in most populations
The New England Comparative Effectiveness Public Advisory Council CEPAC voted that the value of PCSK9 inhibitors Praluent alirocumab and Repatha evolocumab was low except in patients with heterozygous...
View ArticleStudies raise questions about impact of statins on flu vaccination in seniors
A new pair of studies suggests that statins drugs widely used to reduce cholesterol may have a detrimental effect on the immune response to influenza vaccine and the vaccine's effectiveness at...
View ArticleCardioBrief Flu Vaccine Weakened by Statin Use
But association MedPage Today much less causation unproven experts warn
View ArticleMedlab granted ethics approval to begin human trials using nanotechnology...
ÂSOURCE October 23 2015 Sydneybased ASX listed biopharmaceutical company Medlab Clinical Ltd MedlabMDC has been granted ethics approval to progress to two separate human trials using its nanotechnology...
View ArticleAmgen To Highlight Cardiovascular Portfolio At American Heart Association...
THOUSAND OAKS Calif. Nov. 2 2015 PRNewswire Amgen NASDAQAMGN today announced that it will present 14 abstracts at the American Heart Association AHA Scientific Sessions 2015 from Nov. 7&8211;11 in...
View ArticleAmarin Reports Third Quarter 2015 Financial Results and Provides Update on...
BEDMINSTER NJ and DUBLIN IRELANDMarketwired November 04 2015 Amarin Corporation plc NASDAQ AMRN a biopharmaceutical company focused on the commercialization and development of therapeutics to improve...
View ArticleRegeneron Reports Third Quarter 2015 Financial and Operating Results
TARRYTOWN N.Y. Nov. 4 2015 PRNewswire &160;Regeneron Pharmaceuticals Inc. NASDAQ REGN&160;today announced financial results for the third quarter of 2015 and provided an update on development...
View ArticleEsperion Therapeutics Announces Two Oral Presentations for ETC1002 at the...
ANN ARBOR MIMarketwired November 04 2015 Esperion Therapeutics Inc. NASDAQ ESPR a pharmaceutical company focused on developing and commercializing firstinclass oral lowdensity lipoprotein cholesterol...
View ArticleSanofi and Regeneron to Present Results from Phase 3 Praluent alirocumab...
BRIDGEWATER N.J. and TARRYTOWN N.Y. Nov. 5 2015 PRNewswire What&160;Sanofi and Regeneron Pharmaceuticals Inc. today announced that new data from the Praluent clinical trial program will be...
View ArticleEsperion Therapeutics Provides ETC1002 Development Program Update; Reports...
ANN ARBOR MIMarketwired November 05 2015 Esperion Therapeutics Inc. NASDAQ ESPR a pharmaceutical company focused on developing and commercializing firstinclass oral lowdensity lipoprotein cholesterol...
View ArticleEsperion Therapeutics to Present at November Healthcare Conferences
ANN ARBOR MIMarketwired November 06 2015 Esperion Therapeutics Inc. NASDAQ ESPR a pharmaceutical company focused on developing and commercializing firstinclass oral lowdensity lipoprotein cholesterol...
View ArticleLipophilic tops hydrophilic statins for heart failure
HealthDayFor patients with heart failure lipophilic statin is superior to hydrophilic statin for cardiac function and inflammation according to a metaanalysis published in the December issue of...
View ArticleEPA Therapy Added to Statin Therapy Showed Coronary Plaque Regression at...
BEDMINSTER NJ AND DUBLIN IRELANDMarketwired November 09 2015 Amarin Corporation plc NASDAQ AMRN today commented on new data from the CHERRY study that supports the hypothesis under investigation in...
View ArticleHarvard Pilgrim Negotiates FirstInThe Nation Innovative Contract for...
Agreement with Amgen will help to contain costs and improve care Harvard Pilgrim Health Care and Amgen Inc. maker of the new LDL cholesterol lowering drug Repatha have negotiated an agreement that will...
View ArticleAHA Giving Genetic Risk Info Helps Rein in LDL
MedPage Today Lower LDL levels and more statin initiation seen in randomized pilot trial
View ArticleHarvard Pilgrim picks Repatha
Regional insurance company Harvard Pilgrim Health Care Inc. granted Repatha evolocumab from Amgen Inc. NASDAQAMGN exclusive preferred status on its formulary in exchange for undisclosed discounts on...
View ArticleDiadexus Inc. Presents New PLACR Activity Data From the REGARDS Study at 2015...
SOUTH SAN FRANCISCO CA Marketwired 111015 Diadexus Inc. OTCQB DDXS a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk today announced a...
View ArticleMerck's IMPROVEIT FDA Panel Review Has Implications Beyond Zetia Vytorin
Whether FDA agrees that results from ezetimibe cardiovascular outcomes study confirm the LDL hypothesis for nonstatin drugs is of keen interest to sponsors of PSCK9 inhibitors and other novel...
View Article